In this cohort study of 34,131 patients with cancer published in JAMA Oncology, trial ineligibility was associated with a greater likelihood of immune checkpoint inhibitor (ICI) monotherapy use compared with non-ICI therapy. Among trial-ineligible patients, there were no overall survival differences between treatment with ICI monotherapy, ICI combination therapy, and non-ICI therapy.

A new study published in Pediatrics concludes that there is a quick clinical recovery and excellent short-term outcomes for adolescents who develop COVID-19-related vaccination-associated myocarditis (C-VAM). The average age in the study was 15, and close follow-up and further studies are needed to understand the long-term implications and mechanism of these myocardial tissue changes.

The Global Strategy for Asthma Management and Prevention (GINA) has published its annual report on asthma management and prevention. Key recommendations include that adults with asthma should receive combination therapy with an inhaled corticosteroid and a long-acting beta-agonist on an as-needed basis. The recommended option is low-dose budesonide-formoterol, or beclomethasone-formoterol as an alternative treatment. Short-acting inhaled beta agonists as rescue medication is discouraged.

A 59-year-old man is hospitalized with a five-day history of nonproductive cough and fever. The patient reports that he recreationally breeds carrier pigeons and reports no travel outside of the United States. After a physical exam and chest radiograph, what is the most likely cause of this patient’s symptoms?

Among critically ill adults with COVID-19, treatment with convalescent plasma had a low likelihood of providing improvement in organ support–free days, defined as days alive and free of intensive care unit–based organ support.

BMJ’s investigation findings raise questions about data integrity and regulatory oversight concerning Pfizer’s vaccine trial. A regional director told the BMJ that Pfizer falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in the pivotal phase III trial.